Novo Nordisk receives positive 16-0 vote from FDA in favor of approval for semaglutide
Novo Nordisk announced the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted 16-0, supporting the approval of once-weekly semaglutide to improve glycemic control in adults with type 2 diabetes. One member of the committee abstained. October 18, 2017